0000721371-20-000086.txt : 20200806 0000721371-20-000086.hdr.sgml : 20200806 20200806065842 ACCESSION NUMBER: 0000721371-20-000086 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 201079720 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 8-K 1 a20q48k063020form8-kne.htm 8-K Document
false0000721371 0000721371 2020-08-06 2020-08-06 0000721371 2020-05-11 2020-05-11
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2020
 
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
 
 
 
 
 
Ohio
1-11373
 
31-0958666
(State or other
jurisdiction of incorporation)
(Commission
File Number)

 
(IRS Employer
Identification No.)
 
 
 
 
 
 
 
 
 
 
7000 Cardinal Place, Dublin, Ohio 43017
(614) 757-5000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common shares (without par value)
CAH
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   p

 


Item 2.02: Results of Operations and Financial Condition
On August 6, 2020, Cardinal Health, Inc. (the "Company") issued a news release announcing its results for the quarter and fiscal year ended June 30, 2020. A copy of the news release is included as Exhibit 99.1 to this report.
Item 7.01: Regulation FD Disclosure
During a webcast scheduled to be held at 8:30 a.m. Eastern time on August 6, 2020, the Company's Chief Executive Officer and Chief Financial Officer will discuss the Company's results for the quarter and fiscal year ended June 30, 2020 and outlook for the fiscal year ending June 30, 2021. The slide presentation for the webcast will be available on the Investors page at ir.cardinalhealth.com. An audio replay of the webcast also will be available on the Investors page at ir.cardinalhealth.com.
Item 9.01: Financial Statements and Exhibits
(d) Exhibits



2


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Cardinal Health, Inc.
 
 
(Registrant)
 
 
 
 
Date:
August 6, 2020
By:
/s/    JASON M. HOLLAR
 
 
 
Jason M. Hollar
 
 
 
Chief Financial Officer


3
 EX-99.1 2 a20q48k063020exhibit99.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1

essentialtocarea52.jpg
FOR IMMEDIATE RELEASE
Media:
Sarah Shew
 
Investors:
Kevin Moran
 
(614) 553-3401
 
 
(614) 757-7942
 
Sarah.Shew@cardinalhealth.com
 
 
Kevin.Moran@cardinalhealth.com

Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2020

Fourth quarter fiscal 2020 results:
•
Revenue decreased 2% to $36.7 billion

•
GAAP1 operating earnings decreased 12% to $270 million, non-GAAP operating earnings decreased 13% to $442 million

•
GAAP diluted earnings per share were $2.23, non-GAAP diluted earnings per share were $1.04

Full year fiscal 2020 results:
•
Revenue increased 5% to $152.9 billion

•
GAAP operating loss was $4.1 billion, non-GAAP operating earnings increased 1% to $2.4 billion

•
GAAP diluted loss per share was $12.61, non-GAAP diluted earnings per share increased 3% to $5.45

DUBLIN, Ohio, August 6, 2020 - Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2020 revenues of $36.7 billion, a decrease of 2 percent from the fourth quarter last year. GAAP operating earnings were $270 million and non-GAAP operating earnings were $442 million in the quarter, both of which include an estimated net negative impact of approximately $130 million due to the COVID-19 pandemic. GAAP diluted earnings per share (EPS) were $2.23, which included a pre-tax gain of $579 million related to the divestiture of a minority equity interest. Fourth quarter non-GAAP diluted EPS were $1.04.

Fiscal 2020 revenues were $152.9 billion, an increase of 5 percent from fiscal 2019. GAAP operating loss of $4.1 billion includes a $5.6 billion accrual in the first quarter related to opioid litigation. Non-GAAP operating earnings were $2.4 billion for the year. GAAP diluted loss per share for fiscal year 2020 was $12.61, while non-GAAP diluted EPS were $5.45.

“In fiscal 2020, we delivered on our commitments, grew operating earnings and exceeded our EPS guidance, despite the unprecedented global environment,” said Mike Kaufmann, CEO of Cardinal Health. “We play an essential role in healthcare, and I’d like to thank our employees, especially our frontline teams, for their dedication under the challenging circumstances of the past several months. Our strong performance in fiscal 20 and the unwavering commitment of our employees will enable us to manage the complexities ahead, serve our customers and their patients, and continue our growth.”












Cardinal Health
Page 2


Q4 and full year FY20 summary
 
Q4 FY20
 
Q4 FY19
 
Y/Y
 
FY 20
 
FY 19
 
Y/Y
Revenue
$
36.7
 billion
 
$
37.4
 billion
 
(2)%
 
$
152.9
 billion
 
$
145.5
 billion
 
5%
Operating earnings/(loss)
$
270
 million
 
$
307
 million
 
(12)%
 
$
(4.1
) billion
 
$
2.1
 billion
 
N.M.
Non-GAAP operating earnings
$
442
 million
 
$
507
 million
 
(13)%
 
$
2.4
 billion
 
$
2.4
 billion
 
1%
Net earnings/(loss) attributable to Cardinal Health, Inc.
$
656
 million
 
$
194
 million
 
N.M.
 
$
(3.7
) billion
 
$
1.4
 billion
 
N.M.
Non-GAAP net earnings attributable to Cardinal Health, Inc.
$
305
 million
 
$
334
 million
 
(9)%
 
$
1.6
 billion
 
$
1.6
 billion
 
1%
Effective Tax Rate
19.4
%
 
18.4
%
 
 
 
2.1
%
2.0 
22.1
%
 
 
Non-GAAP Effective Tax Rate
26.4
%
 
23.7
%
 
 
 
25.1
%
 
22.1
%
 
 
Diluted EPS attributable to Cardinal Health, Inc.
$
2.23

 
$
0.65

 
N.M.
 
$
(12.61
)
 
$
4.53

 
N.M.
Non-GAAP diluted EPS attributable to Cardinal Health, Inc.
$
1.04

 
$
1.11

 
(6)%
 
$
5.45

 
$
5.28

 
3%

COVID-19
The COVID-19 pandemic adversely affected fourth quarter and fiscal year 2020 results. The negative impact was primarily due to the decline in volumes in both segments related to the cancellation or deferral of elective procedures and physician office visits. The company estimates that the COVID-19 pandemic had a net negative impact to both GAAP and non-GAAP operating earnings of approximately $130 million in the fourth quarter and approximately $100 million in fiscal year 2020.

Segment results

Pharmaceutical segment
 
Q4 FY20
 
Q4 FY19
 
Y/Y
 
FY 20
 
FY 19
 
Y/Y
Revenue
$
33.2
 billion
 
$
33.4
 billion
 
—%
 
$
137.5
 billion
 
$
129.9
 billion
 
6%
Segment profit
$
359
 million
 
$
447
 million
 
(20)%
 
$
1.8
 billion
 
$
1.8
 billion
 
(4)%
Fourth quarter revenue for the Pharmaceutical segment was flat at $33.2 billion. As expected, this reflects the reduced pharmaceutical demand as a result of the accelerated third quarter sales related to COVID-19.

Pharmaceutical segment profit decreased 20 percent to $359 million in the fourth quarter. This reflects expected COVID-19-related volume declines, which primarily affected Nuclear and Precision Health Solutions, as well as the company’s generics program. Pharmaceutical Distribution customer contract renewals also adversely affected segment profit.

Medical segment
 
Q4 FY20
 
Q4 FY19
 
Y/Y
 
FY 20
 
FY 19
 
Y/Y
Revenue
$
3.5
 billion
 
$
4.0
 billion
 
(13)%
 
$
15.4
 billion
 
$
15.6
 billion
 
(1)%
Segment profit
$
120
 million
 
$
97
 million
 
24%
 
$
663
 million
 
$
576
 million
 
15%
Fourth quarter revenue for the Medical segment decreased 13 percent to $3.5 billion due to the adverse effects of cancelled or deferred elective procedures related to COVID-19, primarily on products and distribution.

Medical segment profit increased 24 percent to $120 million in the fourth quarter due to benefits from cost savings initiatives and the beneficial comparison to a supplier-related charge in the prior year. This was partially offset by the adverse effects of COVID-19, primarily on products and distribution.











Cardinal Health
Page 3



Fiscal year 2021 outlook1 
•
Non-GAAP earnings per share
$5.25 - $5.65
•
Interest and other
   $190M - $215M
•
Non-GAAP effective tax rate
24.0% - 26.0%
•
Diluted weighted average shares outstanding
292M - 296M
•
Capital expenditures
  $400M - $450M

Fiscal year 2021 non-GAAP EPS guidance assumes an incremental net headwind related to COVID-19 of a similar year-over-year magnitude as experienced in fiscal 2020. The company expects the adverse impact from the deferral and cancellation of elective procedures and physician office visits to continue, primarily in the first half of the year. The company expects an eventual recovery of elective procedures and physician office visits to pre-COVID-19 levels exiting fiscal 2021. Additionally, demand for personal protective equipment (PPE) products is expected to continue to outpace available supply for the balance of fiscal 2021 due to ongoing global supply challenges. The company anticipates higher costs related to procuring PPE products for customers during the pandemic to be a headwind in fiscal 2021.

The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.

Recent highlights
•
Cardinal Health completed the divestiture of its remaining equity interest in naviHealth.
•
Cardinal Health announced that David Evans, former interim Chief Financial Officer of Cardinal Health, joined the board of directors effective July 1. Mr. Evans previously served as executive vice president and CFO of Battelle Memorial Institute, and as executive vice president and CFO of Scotts Miracle-Gro.
•
Cardinal Health board of directors approved a quarterly dividend of $0.4859 per share. The dividend will be payable on October 15, 2020 to shareholders of record at the close of business on October 1, 2020.
•
Cardinal Health was named to the Human Rights Campaign (HRC) Best Places to Work for LGBTQ Equality for the twelfth consecutive year based on ratings in HRC's 2020 Corporate Equality Index.

Upcoming webcasted investor events
•
Morgan Stanley 18th Annual Global Healthcare Conference at 11:15 a.m. Eastern, Monday, September 14

Webcast
Cardinal Health will host a webcast today at 8:30 a.m. Eastern to discuss fourth quarter and fiscal year results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.

Presentation slides and a webcast replay will be available until August 5, 2021.

About Cardinal Health
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company enhances supply chain efficiency for clinically proven medical products, pharmaceuticals and cost-effective solutions. To combat prescription drug misuse, the Cardinal Health Foundation and its education partners created Generation Rx, a national drug prevention education and awareness program. The Foundation actively supports an array of other solutions, including efforts to reduce opioid prescribing, promote drug take back and safe disposal and expand collaborative community work. Cardinal Health is backed by nearly 100 years of experience with operations in nearly 46 countries. For more information, visit cardinalhealth.com. Follow us on Twitter, Facebook and LinkedIn.




Cardinal Health
Page 4




1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

2The fiscal year 2020 GAAP effective tax rate was impacted by the assessment of the future deductibility of the $5.6 billion opioid litigation accrual and the sale of our remaining equity interest in naviHealth.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.

Cautions Concerning Forward-Looking Statements
This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," “will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include risks arising from the ongoing COVID-19 pandemic and our critical role in the global healthcare supply chain, including the possibility that continued deferrals and cancellations of elective medical procedures will result in a sustained reduction in demand for our products and the possibility that we will not be successful in recouping or offsetting the cost increases to source certain personal protective equipment, or that such cost increases will be larger or more sustained than we currently anticipate, the possibility that we will experience supply disruptions either from new regulations or forced shut downs of distribution or manufacturing facilities; competitive pressures in Cardinal Health's various lines of business; the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture with CVS Health and other components of our generics pharmaceutical program; risks associated with the distribution of opioids, including potential financial impact associated with the outcome of the ongoing lawsuits and investigations by certain governmental and regulatory authorities and the risks associated with the ongoing global settlement framework discussions, including the risk that we may fail to reach a settlement agreement or that a final settlement could require us to pay more than we currently anticipate; risks associated with the manufacture and sourcing of certain products, including risks related to our ability and the ability of third-party manufacturers to comply with applicable regulations; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals; and risks associated with our cost savings initiatives, including the possibility that they could result in greater charges or expenses than we anticipate, could fail to achieve the desired efficiencies or strategic outcomes and could have unintended consequences, such as business disruption. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This release reflects management's views as of August 6, 2020. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.






Schedule 1
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (Unaudited)
 
Fourth Quarter
 
Fiscal Year
(in millions, except per common share amounts)
2020

2019
 
% Change
 
2020
 
2019
 
% Change
Revenue
$
36,689

 
$
37,353

 
(2
)%
 
$
152,922

 
$
145,534

 
5
 %
Cost of products sold
35,099

 
35,679

 
(2
)%
 
146,054

 
138,700

 
5
 %
Gross margin
1,590

 
1,674

 
(5
)%
 
6,868

 
6,834

 
—
 %
 
 
 
 
 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
 
 
 
 
Distribution, selling, general and administrative expenses
1,137

 
1,168

 
(3
)%
 
4,572

 
4,480

 
2
 %
Restructuring and employee severance
42

 
28

 
 
 
122

 
125

 
 
Amortization and other acquisition-related costs
129

 
153

 
 
 
524

 
621

 
 
Impairments and (gain)/loss on disposal of assets, net 1
—

 
3

 
 
 
7

 
(488
)
 
 
Litigation (recoveries)/charges, net 2
12

 
15

 
 
 
5,741

 
36

 
 
Operating earnings/(loss)
270

 
307

 
(12
)%
 
(4,098
)
 
2,060

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Other (income)/expense, net
(22
)
 
2

 
 
 
(1
)
 
15

 
 
Interest expense, net
49

 
67

 
(27
)%
 
238

 
294

 
(19
)%
Loss on early extinguishment of debt
7

 
—

 
 
 
16

 
—

 
 
Gain on sale of equity interest in naviHealth 4
(579
)
 
—

 
 
 
(579
)
 
—

 
 
Earnings/(loss) before income taxes
815

 
238

 
N.M

 
(3,772
)
 
1,751

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Provision for/(benefit from) income taxes 3
158

 
44

 
N.M

 
(79
)
 
386

 
N.M.

Net earnings/(loss)
657

 
194

 
N.M

 
(3,693
)
 
1,365

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Less: Net earnings attributable to noncontrolling interests
(1
)
 
—

 
 
 
(3
)
 
(2
)
 
 
Net earnings/(loss) attributable to Cardinal Health, Inc.
$
656

 
$
194

 
N.M.

 
$
(3,696
)
 
$
1,363

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Earnings/(loss) per common share attributable to Cardinal Health, Inc.:
 
 
 
 
 
 
 
 
 
 
 
Basic
$
2.25

 
$
0.65

 
N.M.

 
$
(12.61
)
 
$
4.55

 
N.M.

Diluted
2.23

 
0.65

 
N.M.

 
(12.61
)
5 

4.53

 
N.M.

 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
 
 
 
 
Basic
292

 
298

 
 
 
293

 
300

 
 
Diluted
294

 
300

 
 
 
293

5 

301

 
 
1 During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).
2 Litigation (recoveries)/charges, net includes a pre-tax charge of $5.63 billion ($5.14 billion after tax) recorded in the first quarter of fiscal 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs. The amount of ultimate loss may differ materially from this accrual.
3 We recorded a tax benefit of $488 million, which is net of unrecognized tax benefits of $469 million, during fiscal 2020, reflecting our current assessment of the estimated future deductibility of the amount that may be paid under the $5.63 billion accrual taken in connection with the opioid litigation described above. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.
4 In the fourth quarter of fiscal 2020, we recognized a $579 million pre-tax gain ($493 million after tax) in connection with the sale of our remaining equity interest in a partnership that owned 100 percent of naviHealth.
5 Due to the net loss during fiscal 2020, potentially dilutive common shares have not been included in the denominator of the dilutive per share computation due to their anti-dilutive effect.





Schedule 2
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)
(in millions)
June 30,
2020
 
June 30,
2019
Assets
 
 
 
Current assets:
 
 
 
Cash and equivalents
$
2,771

 
$
2,531

Trade receivables, net
8,264

 
8,448

Inventories, net
13,198

 
12,822

Prepaid expenses and other
1,707

 
1,946

Total current assets
25,940

 
25,747

 
 
 
 
Property and equipment, net
2,366

 
2,356

Goodwill and other intangibles, net
11,275

 
11,808

Other assets
1,185

 
1,052

Total assets
$
40,766

 
$
40,963

 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
21,374

 
$
21,535

Current portion of long-term obligations and other short-term borrowings
10

 
452

Other accrued liabilities
2,231

 
2,122

Total current liabilities
23,615

 
24,109

 
 
 
 
Long-term obligations, less current portion
6,765

 
7,579

Deferred income taxes and other liabilities
8,594

 
2,945

 
 
 
 
Total shareholders’ equity
1,792

 
6,330

Total liabilities and shareholders’ equity
$
40,766

 
$
40,963




Schedule 3
Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
 
Fourth Quarter
 
Fiscal Year
(in millions)
2020
 
2019
 
2020
 
2019
Cash flows from operating activities:
 
 
 
 
 
 
 
Net earnings/(loss)
$
657

 
$
194

 
$
(3,693
)
 
$
1,365

 
 
 
 
 
 
 
 
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
225

 
241

 
913

 
1,000

Impairments and loss on sale of other investments
—

 
1

 
—

 
3

Gain on sale of equity interest in naviHealth
(579
)
 
—

 
(579
)
 
—

Impairments and (gain)/loss on disposal of assets, net
—

 
4

 
7

 
(488
)
Loss on early extinguishment of debt
7

 
—

 
16

 
—

Share-based compensation
22

 
18

 
90

 
82

Provision for/(benefit from) deferred income taxes
(961
)
 
(83
)
 
(961
)
 
(83
)
Provision for bad debts
20

 
29

 
106

 
88

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
 
 
 
 
 
 
 
(Increase)/decrease in trade receivables
735

 
(595
)
 
82

 
(751
)
Increase in inventories
(401
)
 
(206
)
 
(409
)
 
(551
)
Increase/(decrease) in accounts payable
(610
)
 
1,018

 
(162
)
 
1,864

Other accrued liabilities and operating items, net
1,125

 
(115
)
 
6,550

 
193

Net cash provided by operating activities
240

 
506

 
1,960

 
2,722

 
 
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
 
 
Acquisition of subsidiaries, net of cash acquired
—

 
(44
)
 
—

 
(82
)
Additions to property and equipment
(136
)
 
(136
)
 
(375
)
 
(328
)
Purchases of investments
(2
)
 
(7
)
 
(20
)
 
(18
)
Proceeds from sale of investments
880

 
—

 
886

 
3

Proceeds from divestitures, net of cash sold, and disposal of property and equipment
—

 
14

 
2

 
763

Net cash provided by/(used in) investing activities
742

 
(173
)
 
493

 
338

 
 
 
 
 
 
 
 
Cash flows from financing activities:
 
 
 
 
 
 
 
Net change in short-term borrowings
—

 
—

 
(2
)
 
—

Proceeds from interest rate swap terminations
112

 
—

 
112

 
—

Reduction of long-term obligations, net of issuance costs
(511
)
 
(1,100
)
 
(1,399
)
 
(1,102
)
Net tax proceeds/(withholdings) from share-based compensation
12

 
(1
)
 
8

 
(14
)
Dividends on common shares
(141
)
 
(142
)
 
(569
)
 
(577
)
Purchase of treasury shares
—

 
—

 
(350
)
 
(600
)
Net cash used in financing activities
(528
)
 
(1,243
)
 
(2,200
)
 
(2,293
)
 
 
 
 
 
 
 
 
Effect of exchange rates changes on cash and equivalents
(12
)
 
3

 
(13
)
 
1

 
 
 
 
 
 
 
 
Net increase/(decrease) in cash and equivalents
442

 
(907
)
 
240

 
768

Cash and equivalents at beginning of period
2,329

 
3,438

 
2,531

 
1,763

Cash and equivalents at end of period
$
2,771

 
$
2,531

 
$
2,771

 
$
2,531





Schedule 4
Cardinal Health, Inc. and Subsidiaries
Segment Information


    
Fourth Quarter
 
 
 
 
 
 
 
 
 
(in millions)
2020
 
2019
 
(in millions)
2020
 
2019
Pharmaceutical
 
 
 
 
Medical
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
 
 
 
Revenue
 
 
 
Amount
$
33,241

 
$
33,401

 
Amount
$
3,453

 
$
3,956

Growth rate
—
 %
 
6
%
 
Growth rate
(13
)%
 
1
 %
 
 
 
 
 
 
 
 
 
Segment profit
 
 
 
 
Segment profit
 
 
 
Amount
$
359

 
$
447

 
Amount
$
120

 
$
97

Growth rate
(20
)%
 
7
%
 
Growth rate
24
 %
 
(15
)%
Segment profit margin
1.08
 %
 
1.34
%
 
Segment profit margin
3.49
 %
 
2.45
 %
Fiscal Year
 
 
 
 
 
 
 
 
 
(in millions)
2020
 
2019
 
(in millions)
2020
 
2019
Pharmaceutical
 
 
 
 
Medical
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
 
 
 
Revenue
 
 
 
Amount
$
137,495

 
$
129,917

 
Amount
$
15,444

 
$
15,633

Growth rate
6
 %
 
7
 %
 
Growth rate
(1
)%
 
—
 %
 
 
 
 
 
 
 
 
 
Segment profit
 
 
 
 
Segment profit
 
 
 
Amount
$
1,753

 
$
1,834

 
Amount1
$
663

 
$
576

Growth rate
(4
)%
 
(8
)%
 
Growth rate
15
 %
 
(13
)%
Segment profit margin
1.28
 %
 
1.41
 %
 
Segment profit margin
4.30
 %
 
3.68
 %
1 Medical segment profit for fiscal 2020 does not include $85 million incurred for inventory write-offs and certain remediation and supply disruption costs associated with fiscal 2020 voluntary surgical gown-related recalls.
The sum of the components and certain computations may reflect rounding adjustments.





Schedule 5
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1 

 
 












 
Gross



Operating
Earnings


Net


Diluted

 
Margin

SG&A2

Earnings
Before
Provision for

Earnings3
Effective

EPS3

Gross
Growth

Growth
Operating
Growth
Income
Income
Net
Growth
Tax
Diluted
Growth
(in millions, except per common share amounts)
Margin
Rate
SG&A2
Rate
Earnings
Rate
Taxes
Taxes
Earnings3
Rate
Rate
EPS3
Rate
Fourth Quarter 2020
GAAP
$
1,590

(5
)%
$
1,137

(3
)%
$
270

(12
)%
$
815

$
158

$
656

N.M.

19.4
%
$
2.23

N.M.

Surgical gown recalls costs
(7
)
 
3

 
(10
)
 
(10
)
(3
)
(7
)
 
 
(0.02
)
 
State opioid assessment related to prior fiscal years
—

 
1


(1
)

(1
)
—

(1
)


—


Restructuring and employee severance
—

 
—


42


42

10

32



0.11


Amortization and other acquisition-related costs
—

 
—


129


129

32

97



0.33


Litigation (recoveries)/charges, net
—

 
—


12


12

5

7





0.02



Loss on early extinguishment of debt
—

 
—


—


7

2

5



0.02


Gain on sale of equity interest in naviHealth
—


—


—


(579
)
(86
)
(493
)




(1.68
)


Transitional tax benefit, net
—

 
—


—


—

(9
)
9



0.03


Non-GAAP
$
1,583

(5
)%
$
1,141

(2
)%
$
442

(13
)%
$
415

$
110

$
305

(9
)%
26.4
%
$
1.04

(6
)%

Fourth Quarter 2019
GAAP
$
1,674

(4
)%
$
1,168

(8
)%
$
307

N.M

$
238

$
44

$
194

N.M.

18.4
%
$
0.65

N.M.

Restructuring and employee severance
—

 
—


28


28

7

21



0.07


Amortization and other acquisition-related costs
—

 
—


153


153

35

118



0.39


Impairments and (gain)/loss on disposal of assets, net
—

 
—


3


3

15

(12
)


(0.04
)

Litigation (recoveries)/charges, net
—

 
—


15


15

3

12



0.04


Transitional tax benefit, net
—

 
—


—


—

(1
)
1



—


Non-GAAP
$
1,674

(4
)%
$
1,168

(8
)%
$
507

9
 %
$
438

$
103

$
334

6
 %
23.7
%
$
1.11

10
 %
1For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
2Distribution, selling, general and administrative expenses.
3Attributable to Cardinal Health, Inc.
The sum of the components and certain computations may reflect rounding adjustments.
We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.














Schedule 5
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1 

 
 



Operating
Earnings/


Net




 
Gross



Earnings/
(Loss)
Provision for/

Earnings/


Diluted

 
Margin

SG&A2
Operating
(Loss)
Before
(Benefit from)
Net
(Loss)3
Effective

EPS3

Gross
Growth

Growth
Earnings/
Growth
Income
Income
Earnings/
Growth
Tax
Diluted
Growth
(in millions, except per common share amounts)
Margin
Rate
SG&A2
Rate
(Loss)
Rate
Taxes
Taxes
(Loss)3
Rate
Rate
EPS3,4
Rate
Fiscal Year 2020
GAAP
$
6,868

—
 %
$
4,572

2
 %
$
(4,098
)
N.M

$
(3,772
)
$
(79
)
$
(3,696
)
N.M.

2.1
%
$
(12.61
)
N.M.

Surgical gown recalls costs
48

 
(37
)
 
85

 
85

22

63

 
 
0.22

 
State opioid assessment related to prior fiscal years
—

 
(3
)

3


3

1

2



0.01


Restructuring and employee severance
—

 
—


122


122

29

93



0.31


Amortization and other acquisition-related costs
—

 
—


524


524

130

394



1.34


Impairments and (gain)/loss on disposal of assets
—

 
—


7


7

2

5



0.02


Litigation (recoveries)/charges, net 5
—

 
—


5,741


5,741

514

5,227



17.84


Loss on early extinguishment of debt
—

 
—


—


16

4

12



0.04


Gain on sale of equity interest in naviHealth
—


—


—


(579
)
(86
)
(493
)


(1.68
)

Transitional tax benefit, net
—

 
—


—


—

2

(2
)


(0.01
)

Non-GAAP
$
6,916

1
 %
$
4,532

1
 %
$
2,384

1
 %
$
2,147

$
539

$
1,605

1
%
25.1
%
$
5.45

3
%

Fiscal Year 2019
GAAP
$
6,834

(5
)%
$
4,480

(3
)%
$
2,060

N.M.

$
1,751

$
386

$
1,363

N.M.

22.1
%
$
4.53

N.M.

Restructuring and employee severance
—

 
—


125


125

32

93



0.31


Amortization and other acquisition-related costs
—

 
—


621


621

148

473



1.57


Impairments and (gain)/loss on disposal of assets, net 6
—

 
—


(488
)

(488
)
(113
)
(375
)


(1.25
)

Litigation (recoveries)/charges, net
—

 
—


36


36

10

26



0.09


Transitional tax benefit, net
—

 
—


—


—

(9
)
9



0.03


Non-GAAP
$
6,834

(5
)%
$
4,480

(3
)%
$
2,353

(9
)%
$
2,044

$
453

$
1,589

1
%
22.1
%
$
5.28

6
%
1For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.
2Distribution, selling, general and administrative expenses.
3Attributable to Cardinal Health, Inc.
4For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.
5Litigation (recoveries)/charges, net includes a pre-tax charge of $5.63 billion ($5.14 billion after tax) recorded in the first quarter of fiscal 2020 related to the opioid litigation.
6 During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).

The sum of the components and certain computations may reflect rounding adjustments.
We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.



Cardinal Health, Inc. and Subsidiaries

Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (“GAAP").
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•
LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•
Surgical gown recall costs includes inventory write-offs and certain remediation and supply disruption costs arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•
State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the fiscal year of the initial assessment. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Reversals of these accruals have occurred when certain assessments were found by a Court unconstitutional.
•
Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.
•
Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
•
Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•
Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
•
Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
•
Gain on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.


•
Transitional tax benefit, net related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.
The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.


Forward Looking Non-GAAP Measures
In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.
The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company’s fiscal 2021 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company’s EPS from $0.75 to $18.06, which includes a goodwill impairment charge of $4.36 per share related to our Medical segment that we recognized in fiscal 2018. The excluded items for fiscal 2020 impacted the Company's EPS by $18.06, which includes a $17.54 charge related to the opioid litigation.

Definitions

Growth rate calculation: growth rates in this earnings release are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Interest and Other, net: other (income)/expense, net plus interest expense, net.
Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits) and surgical gown recall costs.
Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding surgical gown recall costs and state opioid assessment related to prior fiscal years.
Non-GAAP operating earnings: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) gain on sale of equity interest in naviHealth.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) gain on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net.
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) gain on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net divided by (earnings before income taxes adjusted for the first nine items).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.


 EX-101.SCH 3 cah-20200806.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 cah-20200806_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 cah-20200806_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 cah-20200806_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 cah-20200806_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 essentialtocarea52.jpg begin 644 essentialtocarea52.jpg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end XML 9 a20q48k063020form8-kne_htm.xml IDEA: XBRL DOCUMENT 0000721371 2020-08-06 2020-08-06 0000721371 2020-05-11 2020-05-11 false 0000721371 8-K 2020-08-06 Cardinal Health, Inc. OH 1-11373 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 false false false false Common shares (without par value) CAH NYSE false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page
Aug. 06, 2020
May 11, 2020
Cover [Abstract]    
Document Type 8-K  
Document Period End Date Aug. 06, 2020  
Entity Registrant Name Cardinal Health, Inc.  
Entity Incorporation, State or Country Code   OH
Entity File Number   1-11373
Entity Tax Identification Number   31-0958666
Entity Address, Address Line One 7000 Cardinal Place  
Entity Address, City or Town Dublin  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43017  
City Area Code 614  
Local Phone Number 757-5000  
Written Communications false  
Soliciting Material false  
Pre-commencement Tender Offer false  
Pre-commencement Issuer Tender Offer false  
Title of 12(b) Security Common shares (without par value)  
Trading Symbol CAH  
Security Exchange Name NYSE  
Entity Emerging Growth Company false  
Entity Central Index Key   0000721371
Amendment Flag   false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 2 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports a20q48k063020form8-kne.htm a20q48k063020exhibit99.htm cah-20200806.xsd cah-20200806_cal.xml cah-20200806_def.xml cah-20200806_lab.xml cah-20200806_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20q48k063020form8-kne.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 2, "dts": { "calculationLink": { "local": [ "cah-20200806_cal.xml" ] }, "definitionLink": { "local": [ "cah-20200806_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "a20q48k063020form8-kne.htm" ] }, "labelLink": { "local": [ "cah-20200806_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cah-20200806_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cah-20200806.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20200806", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a20q48k063020form8-kne.htm", "contextRef": "D2020Q4earns", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a20q48k063020form8-kne.htm", "contextRef": "D2020Q4earns", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000721371-20-000086-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-20-000086-xbrl.zip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end